JP2009520825A - グルコキナーゼ活性剤 - Google Patents

グルコキナーゼ活性剤 Download PDF

Info

Publication number
JP2009520825A
JP2009520825A JP2008547525A JP2008547525A JP2009520825A JP 2009520825 A JP2009520825 A JP 2009520825A JP 2008547525 A JP2008547525 A JP 2008547525A JP 2008547525 A JP2008547525 A JP 2008547525A JP 2009520825 A JP2009520825 A JP 2009520825A
Authority
JP
Japan
Prior art keywords
alkyl
hetero
cycloalkyl
bicycloaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2008547525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009520825A5 (enExample
Inventor
フェン、ジュン
エル． グワルトニー、ステファン
ジェイ． ホスフィールド、デイヴィッド
茂和 佐々木
ジェイ． スキーン、ロバート
ウォレス、マイケル、ビー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2009520825A publication Critical patent/JP2009520825A/ja
Publication of JP2009520825A5 publication Critical patent/JP2009520825A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2008547525A 2005-12-20 2006-12-19 グルコキナーゼ活性剤 Abandoned JP2009520825A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75275005P 2005-12-20 2005-12-20
PCT/US2006/048714 WO2007075847A2 (en) 2005-12-20 2006-12-19 Glucokinase activators

Publications (2)

Publication Number Publication Date
JP2009520825A true JP2009520825A (ja) 2009-05-28
JP2009520825A5 JP2009520825A5 (enExample) 2009-12-17

Family

ID=38051016

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008547525A Abandoned JP2009520825A (ja) 2005-12-20 2006-12-19 グルコキナーゼ活性剤

Country Status (5)

Country Link
US (1) US20070244169A1 (enExample)
EP (1) EP1966152A2 (enExample)
JP (1) JP2009520825A (enExample)
CA (1) CA2633584A1 (enExample)
WO (1) WO2007075847A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506248A (ja) * 2014-02-20 2017-03-02 コーネル ユニヴァーシティー ファシンを阻害するための化合物及び方法

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素５員複素環化合物
EP2157859A4 (en) * 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
WO2009012312A1 (en) * 2007-07-16 2009-01-22 Abbott Laboratories Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009097318A1 (en) * 2008-01-28 2009-08-06 Bristol-Myers Squibb Company A fluorescence polarization binding assay for characterizing glucokinase ligands
US8349886B2 (en) 2008-04-16 2013-01-08 Takeda Pharmaceutical Company Limited Nitrogenated 5-membered heterocyclic compound
GEP20135783B (en) * 2008-05-16 2013-03-11 Takeda California Inc Glucokinase activators
DE102009004245A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
KR20170093264A (ko) 2009-03-11 2017-08-14 오메로스 코포레이션 중독의 예방 및 치료용 조성물 및 방법
JP2013510834A (ja) 2009-11-16 2013-03-28 メリテク ［１，５］‐ジアゾシン誘導体
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
WO2011143430A1 (en) 2010-05-12 2011-11-17 Abbott Laboratories Indazole inhibitors of kinase
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
DK2880167T3 (en) 2012-07-31 2018-07-30 Univ Texas METHODS AND COMPOSITIONS FOR IN VIVO-INDUCTION OF PANCREAS BETA CELL CREATION
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
CA2969540C (en) 2014-12-02 2023-03-21 Ignyta, Inc. Combinations for the treatment of neuroblastoma
US10221172B2 (en) 2015-01-13 2019-03-05 Vanderbilt University Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2017106492A1 (en) 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer
KR102718538B1 (ko) 2017-07-19 2024-10-21 이그니타, 인코포레이티드 엔트렉티닙을 포함하는 약학적 조성물
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
CN110117278B (zh) * 2018-02-07 2022-07-19 石家庄以岭药业股份有限公司 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
CN110015975A (zh) * 2019-05-14 2019-07-16 浙江长华科技股份有限公司 一种2-氯-5-硝基苯甲腈微反应合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2653005A1 (de) * 1975-12-03 1977-06-08 Sandoz Ag Neue organische verbindungen, ihre verwendung und herstellung
US6638926B2 (en) * 2000-09-15 2003-10-28 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6593349B2 (en) * 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
EP1537087B1 (fr) * 2002-09-05 2012-11-28 Aventis Pharma S.A. Derives de 3-aminoindazole comme inhibiteurs de kinase et compositions pharmaceutiques les renfermant
WO2004062662A1 (fr) * 2002-12-12 2004-07-29 Aventis Pharma S.A. Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
EP1532980A1 (en) * 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506248A (ja) * 2014-02-20 2017-03-02 コーネル ユニヴァーシティー ファシンを阻害するための化合物及び方法

Also Published As

Publication number Publication date
WO2007075847A3 (en) 2007-10-04
WO2007075847A2 (en) 2007-07-05
CA2633584A1 (en) 2007-07-05
EP1966152A2 (en) 2008-09-10
US20070244169A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
JP2009520825A (ja) グルコキナーゼ活性剤
JP5302012B2 (ja) グルコキナーゼ活性剤
JP5513492B2 (ja) グルコキナーゼ活性剤
JP5386350B2 (ja) グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
US8163779B2 (en) Glucokinase activators
US8173645B2 (en) Glucokinase activators
JP2010508307A (ja) Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
JP2010522191A (ja) Ｍａｐｋ／ｅｒｋキナーゼ阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091028

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20110817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110817